KEYNOTE-859: Presentation by Dr. Kai-Keen Shiu

Prescribing Information [External link]

Video Player is loading.

Play Video

PlaySkip BackwardSkip Forward

Mute

Current Time 0:00

/

Duration 3:55

Loaded: 2.49%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -3:55

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Subtitles

• subtitles settings, opens subtitles settings dialog
• subtitles off, selected

Audio Track

• en (Main), selected

Picture-in-PictureFullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-Transparent

Text Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-TransparentTransparent

Caption Area Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDrop shadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

ResetDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Length: 03:55

Dr. Kai-Keen Shiu, Consultant Medical Oncologist at the UCL Cancer Institute, describes results from the KEYNOTE-859 trial for patients with locally advanced unresectable or metastatic HER2-negative gastric or GOJ adenocarcinoma expressing PD-L1 with a CPS ≥ 1 . ¹

CPS = combined positive score; GOJ = gastro-oesophageal junction; HER2 = human epidermal growth factor receptor 2; PD-L1 = programmed death ligand 1

More information about KEYTRUDA® (pembrolizumab) in locally advanced unresectable or metastatic gastro-oesophageal cancer.

References

1. Rha SY, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology. 2023 Nov; 24(11):1181-1195.

Supporting documentation

Prescribing Information [External link] 
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.